Authors
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
How MSLs Can Enrich Scientific Exchange with Customer InsightIn today‘s environment, medical science liaisons (MSLs) must call on digital solutions to make use of the right data and encourage the right conversations to take place.
Latest:
What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug DevelopmentIndustry has shown it can overcome challenges en route to creating new therapies.
Latest:
Improving Readiness for Volume-Based Procurement in ChinaVolume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
Latest:
Building Crisis Management and Risk Mitigation Plans into Patient Support ProgramsIn simple terms, patient support programs help get medicines into the hands of people who need them.
Latest:
No Half Measures: How Medical Affairs Can Maximize and Measure ValueEducation and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
Latest:
Key Considerations for Senior Executives Related to Quality CultureExploring practical points to further understand and strengthen quality culture.
Latest:
5 Lessons Learned from Embracing Agile in Commercial LaunchAgile methodologies provide an alternative to hierarchical, siloed and sequential way of managing activities and have the potential to dramatically reduce set-up time for new business or digital capabilities.
Latest:
Understanding the HCP: Patient-Level Data Proves ValuableEvaluating patient data in the context of complementary information can provide comprehensive market insights for product strategy.
Latest:
Embracing Generative AI: Why Its Disruption is Positive for PharmaThe new era of generative AI is poised to impact pharma marketing and engagement in powerful and lasting ways. But amid all the technological praise, what are the key considerations brand teams must navigate?
Latest:
Measuring Pharma’s Trust PerformanceThe core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Latest:
The American Rescue Plan Act of 2021: Pharmaceutical Industry ImpactAssessing the implications for the pharma industry of the America Rescue Plan Act of 2021, which provides nearly two trillion dollars in funding for various government programs, including many related to public health.
Latest:
Billing Codes for DTx Would Open the Floodgates for Behavioral Health EquityApproval of Medicare and Medicaid coverage for digital therapeutics represents next step in advancing care for mental health patients.
Latest:
Emergency Use Authorization: What We’ve Learned Bringing COVID-19 Therapies to MarketPandemic forces pharma companies to work faster and smarter to meet hard deadlines.
Latest:
As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally AdaptU.S. patent law will have to adapt to the use of AI in the life sciences industry.
Latest:
Transforming Healthcare Data to Precision MedicineA modern healthcare ecosystem involves various stakeholders and many forms of complex data. Collaborations and a range of advanced approaches are essential to providing more uniform and complete healthcare to patients.
Latest:
Empathy: The Foundation of Health LiteracyGoing beyond the words of healthcare communication.
Latest:
Triggering Script Lifts: Strategic Imperatives in Real-Time Pharmaceutical MarketingData utilization in real-time targeting is a linchpin for success in navigating the intricacies of contemporary pharmaceutical marketing dynamics.
Latest:
Partnering to Respond to a Possible Nuclear ThreatRecent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Latest:
Staying the Course: Double Down on Launch AgilityIn today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.
Latest:
China’s 2022 NRDL OutlookThe 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.
Latest:
The Top 5 Golden Opportunities for Pharma RecruitmentPharma companies must revise their recruitment strategies in the wake of a skills shortage.
Latest:
Balancing Costs and Data Integrity: Maximizing ROI with Lab Software Solutions (December 2023)Explore the implementation of enterprise laboratory software and the start of a digital transformation in your lab with an industry expert who discusses maximizing returns on investment, upholding data integrity while managing cost containment, and adopting digital best practices. This podcast addresses critical topics such as cybersecurity, regulatory compliance and fiscal strategy for pharmaceutical labs and offers valuable insights for professionals at the crossroads of technology, finance, and pharmaceutical regulations. Discover how laboratories can use software solutions to surpass industry standards while managing costs with Bob Voelkner, Vice President, Sales and Marketing, LabVantage Solutions, Inc.
Latest:
The EU Regulations Catching US Pharma Companies Off GuardCompanies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
Latest:
NFTs: What This New Kid on the Blockchain Means for HealthcareThere has been a push to implement NFTs, or non-fungible tokens, across many verticals, but there is still much to learn about their potential uses in healthcare and its brands.
